Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review

Alice Zwerling,1 Susan van den Hof,2,3 Jerod Scholten,2 Frank Cobelens,2,3 Dick Menzies,1 Madhukar Pai1

ABSTRACT

Healthcare workers (HCWs) are at increased risk of exposure to tuberculosis (TB). Traditionally, screening for latent TB infection (LTBI) is done using the tuberculin skin test (TST). Interferon-gamma release assays (IGRAs) are now increasingly being used for diagnosis of LTBI, but their role in HCW screening is unclear. A systematic review was conducted of all IGRA studies in HCWs to summarise their performance in cross-sectional and serial testing settings. By searching four electronic databases and other sources, all available studies using any one of the commercial IGRA assays in HCWs were retrieved and screened. 50 unique studies were identified which met the inclusion criteria including five from high TB incidence settings. Among 24 cross-sectional studies in low TB incidence settings, the pooled prevalence of positive IGRA using either test was significantly lower than for a positive TST. However, in high-incidence settings (n=2) there were no consistent differences in the prevalence of positive tests. IGRAs showed good correlation with occupational risk factors for TB exposure in low-incidence settings. Only 10 studies assessed use of IGRA for serial testing and all showed large variation in the rates of conversions and reversions, with no data suggesting that IGRAs are better at identifying the incidence of new TB infection than the TST. The use of IGRAs instead of TST for one-time screening may result in a lower prevalence of positive tests and fewer HCWs who require LTBI treatment, particularly in low TB incidence settings. However, the use of IGRA for serial testing is complicated by lack of data on optimum cut-offs for serial testing and unclear interpretation and prognosis of conversions and reversions. Further longitudinal research will be required to inform guidelines on serial testing using IGRA.

INTRODUCTION

Tuberculosis (TB) continues to have a significant health impact worldwide with an estimated one-third of the world’s population infected with latent TB (LTBI). TB poses a significant occupational health problem and healthcare workers (HCWs) are at increased risk of exposure to TB.1,2 A systematic review of 51 studies showed that the prevalence and incidence of TB infection and disease were high among HCWs in low and middle income countries.3 The emergence of extensively drug-resistant TB has resulted in a renewed interest and emphasis on the protection of the healthcare workforce. The World Health Organization (WHO) recently issued a policy on TB infection control (TBIC) in resource-limited settings and is now actively promoting TBIC programmes.3

In many high-income countries, periodic screening of HCWs for LTBI is an important component of TBIC programmes.4 Traditionally, the prevalence of LTBI and incidence of new TB infection (ie, conversion) among HCWs has been estimated using the tuberculin skin test (TST), a test with known limitations.5–7 Recently, interferon-gamma release assays (IGRAs) have emerged as alternatives for the diagnosis of LTBI.5–10 Two IGRA are commercially available—the Quantiferon-TB Gold In-Tube (QFT) assay (Cellestis Ltd, Carnegie, Australia) and the T-SPOT.TB assay (Oxford Immunotec, Abingdon, UK). With the development of new national guidelines incorporating IGRA, their use is steadily increasing.11 IGRA have features that make them attractive for repeated screening: they are ex vivo blood-based tests that, in contrast to the TST, can be repeated any number of times without sensitisation or boosting, they require only one visit and do not need a baseline two-step protocol.

There is strong evidence from systematic reviews that IGRA, especially QFT, have excellent specificity that is unaffected by BCG vaccination, while the T-SPOT.TB shows improved sensitivity for active TB over both the TST and QFT.12–13 However, reviews have suggested that IGRA performance differs in high versus low TB incidence settings, with relatively lower sensitivity in high-incidence countries.9,14

Despite the substantial body of literature on IGRA, almost all the available studies have limitations—namely, lack of a gold standard for LTBI, cross-sectional design, use of sensitivity and specificity as surrogates for patient-important outcomes, and lack of adequate data on predictive/prognostic value of IGRA. In particular, data are lacking on how to interpret repeated (serial) IGRA testing results.15–16 Currently, no guidelines exist on the use of IGRA in countries with a high incidence of TB. Some guidelines from high-income low-incidence countries have not recommended IGRA for serial testing of HCWs17 while others state that IGRA may be used for serial testing of HCWs in place of the TST.4,9

METHODS

Our objective was systematically to review all studies using IGRA to test HCWs, including cross-sectional, longitudinal and serial testing studies, to summarise their performance characteristics. Secondary objectives included (1) to compare IGRA performance in HCWs in high or low TB incidence settings; (2) to determine if IGRA are better...
correlated with occupational exposure to TB than the TST in cross-sectional studies; (3) to estimate the rate of IGRA conversions and reversions and assess whether IGRA conversions are more closely associated with recent occupational exposure than TST conversions; and (4) to summarise the evidence produced by cost-effectiveness analyses and programmatic studies.

**Data sources and searches**

We have previously published systematic and narrative reviews on IGRA accuracy and performance in various subgroups. We updated the database searches used in previous systematic reviews and searched the literature for relevant IGRA studies. PubMed, Embase and Biosis and Web of Science were searched and citations of all original articles published in all languages up to 30 April 2010 that reported data on IGRA performance in HCWs (updated again on 1 October 2010 to include the most recent serial testing studies) were reviewed.

In addition to database searches we reviewed bibliographies of previous reviews and guidelines on IGRA, conference proceedings, abstracts and also screened the citations of relevant original articles. Experts in the field and commercial test manufacturers were contacted to obtain relevant citations. Authors of primary studies were contacted to obtain additional information where necessary. The detailed search string and a list of conferences reviewed for relevant citations are available in the online supplement.

**Outcomes evaluated**

A major challenge for studies evaluating the performance of IGRA is the lack of a gold standard for LTBI. We therefore developed a priori a hierarchy of reference standards for the performance of IGRA in diagnosing LTBI in HCWs (figure 1). At the time of this review, there was no evidence at the highest two levels of the hierarchy nor were there studies looking at sensitivity and specificity for active TB in HCWs. We therefore evaluated studies that reported one or more of the following outcomes: prevalence and incidence of LTBI; correlation between IGRA results and an exposure gradient; and/or agreement between IGRA and TST results.

Details of study selection, inclusion and exclusion criteria, data extraction procedure and quality assessment are given in the online supplement.

**Data synthesis and analysis**

Study characteristics and results are presented as tables and plots. In order to compare prevalence estimates for the tests (IGRA vs TST) we calculated Fisher exact 95% CIs for the prevalence estimates extracted from the original reports. If the 95% CIs did not overlap, differences between proportions were considered as statistically significant, a conservative approach. For the association between occupational risk factors and IGRA we extracted ORs reported by the original authors. When available we extracted both crude and adjusted ORs. Because the included studies varied greatly in their design, execution and outcomes, and because meta-analysis methods are not well defined for such heterogeneous diagnostic studies with no gold standard, we did not perform a meta-analysis. IGRA performance varies across populations so all the results were stratified by TB incidence in the country where the study was done (high vs intermediate and low incidence). High-incidence countries were defined as countries with more than 100 estimated incident TB cases per year per 100 000 population as determined by the WHO.

**RESULTS**

**Description of included studies**

Figure 2 shows a flow chart on study selection. The final tables included 42 IGRA studies in HCWs that reported one of our main outcomes of interest. In addition we identified three studies on cost-effectiveness of IGRA in HCWs and three studies on feasibility and test implementation. Finally, two new serial testing studies were identified by 1 October 2010, giving a total of 50 studies of IGRA in HCWs. The characteristics of the cross-sectional and serial testing studies identified in this review are shown in tables 1 and 2, respectively. Complete details on study methodology and test performance are given in appendix tables A1 and A2, respectively, in the online supplement. Data are presented stratified by high versus low and moderate TB incidence settings but, even within these strata, the study populations included HCWs with varying risk of TB exposure.

Of the 44 included studies reporting a main outcome, 35 (79%) evaluated QFT only and 3 (7%) used T-SPOT.TB only, while the remaining 6 (14%) evaluated both IGRA. While most studies performed both an IGRA and the TST, 14% of studies only performed IGRA testing and therefore could not compare IGRA results with TST results. Overall, only 5 (11%) were done in high-incidence settings. Only 10 (23%) used a longitudinal or serial testing design. Study sizes ranged from 12 to 1313 HCWs, for a total of 11 963 HCWs across the 44 studies. Most included BCG-vaccinated HCWs; however, the proportion of BCG-vaccinated HCWs varied considerably (7–100%).

**Results of cross-sectional IGRA studies**

**IGRA versus TST positivity rates in HCW populations in high-incidence countries**

Three cross-sectional studies evaluated IGRA performance in HCWs in India, Russia and Vietnam, although TST was not performed in the Russian study. As shown in figure 3, TST and IGRA positivity rates were high in HCWs (40–66%); IGRA positivity was slightly lower than TST positivity in the studies in India and Vietnam comparing TST and IGRA, but the difference in estimated prevalence between the two tests was significant only in Vietnam. The Vietnamese study also reported the lowest rate of BCG vaccination among its participants at 57.3% compared with 71% in the Indian study.

**IGRA versus TST positivity rates in HCW populations in low- and moderate-incidence countries**

We identified 31 cross-sectional studies from low or intermediate TB incidence countries. Twenty-five studies used only
the QFT-Gold test, 2 studies only the T-SPOT.TB and 4 performed head-to-head comparisons of the QFT and T-SPOT.TB tests. The prevalence of positive QFT ranged from 1% to 66.8% and of positive T-SPOT.TB tests from 1% to 60%. Among 25 studies that compared IGRA with TST, all but one reported a lower prevalence of positive QFT or T-SPOT.TB than positive TST (figures 3 and 4), with statistically significant differences found in 17 of these 24 studies. The studies in figure 4 are shown in order of increasing proportion of participants BCG vaccinated; studies in which a higher proportion of study participants were BCG vaccinated did not necessarily have a higher prevalence of positive TST or a larger difference between the prevalence of positive TST and positive IGRA.

Concordance was weak between TST and IGRAs in these studies with k values ranging widely from 0.05 in Denmark (using a 12 mm TST cut-off) to 0.56 in a study from Spain (using a 15 mm TST cut-off for BCG-vaccinated individuals). Three studies evaluated a range of TST cut-offs in the analysis and all showed that agreement could be improved by employing a more stringent TST cut-off (ie, 15 mm vs 10 mm). In all 19 studies that reported on discordance, TST+/IGRA— subjects was the predominant type of discordance.

In summary, among these 34 cross-sectional studies the prevalence of positive IGRA was lower than positive TST. The difference in prevalence was significant in low and moderate TB incidence settings (figure 4) but not in high-incidence settings.

Association between occupational risk factors and test results in HCW populations

The majority of studies reporting such analyses were done in low-incidence settings. Of three cross-sectional studies conducted in high-incidence settings, only Pai et al evaluated associations between occupational risk factors and both TST and IGRA. They found a stronger but non-significant association between occupational risk factors and IGRA positivity than the TST.

Of the 31 cross-sectional studies conducted in low-incidence countries, 22 evaluated potential risk factors for IGRA and/or TST positivity rates. Fourteen studies reported a positive association between IGRA positivity and occupational risk factors, including higher risk for clinical staff working in a high-risk ward, TB clinic or geriatric care and increased duration of healthcare employment. Two studies reported no association between test positivity and risk factors; the remaining studies either did not perform the TST or did not calculate ORs for risk factors associated with test positivity. The age-adjusted ORs for TST and IGRAs and occupational risk factors for relevant studies are compared in figure 5; all studies are from low- and moderate-incidence countries with the exception of the India study. All three tests correlated well with established indicators of occupational risk of TB exposure, although no test was consistently more often associated with these indicators of exposure. Being of foreign birth or having lived in a high TB incidence country was correlated with QFT positivity in four studies and with TST in one study.

From these cross-sectional studies, IGRAs appear to be well correlated with TB infection risk factors (including occupational risk factors) in HCWs in low- and intermediate-incidence countries.
### Table 1  Characteristics of 34 cross-sectional IGRA studies in HCWs

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Country</th>
<th>N</th>
<th>TST (PPD dose)</th>
<th>IGRA (QFT, TSPOT.TB or both)</th>
<th>BCG vaccinated (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High TB incidence countries</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pai et al 22,32</td>
<td>2005</td>
<td>India</td>
<td>726</td>
<td>1 TU</td>
<td>QFT-G-IT</td>
<td>71</td>
</tr>
<tr>
<td>Dobrniakiewicz et al 23</td>
<td>2007</td>
<td>Russia</td>
<td>500</td>
<td></td>
<td>QFT-G-IT</td>
<td>84</td>
</tr>
<tr>
<td>Liu et al 45,46</td>
<td>2009</td>
<td>Vietnam</td>
<td>300</td>
<td>5 TU</td>
<td>QFT-G-IT</td>
<td>37.3</td>
</tr>
<tr>
<td><strong>Intermediate and low TB incidence countries</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang et al 24</td>
<td>2005</td>
<td>Republic of Korea</td>
<td>171</td>
<td>2 TU</td>
<td>QFT-G</td>
<td>92.3</td>
</tr>
<tr>
<td>Harada et al 26</td>
<td>2006</td>
<td>Japan</td>
<td>332</td>
<td>2.5 TU</td>
<td>T-SPOT.TB</td>
<td>91.3</td>
</tr>
<tr>
<td>Ozkinci et al 37</td>
<td>2007</td>
<td>Turkey</td>
<td>66</td>
<td>5 IU</td>
<td>QFT-G</td>
<td>67</td>
</tr>
<tr>
<td>Veeer et al 28</td>
<td>2007</td>
<td>USA</td>
<td>55</td>
<td></td>
<td>QFT-G</td>
<td>45</td>
</tr>
<tr>
<td>Soborg et al 29</td>
<td>2007</td>
<td>Denmark</td>
<td>139</td>
<td>2 TU</td>
<td>QFT-G</td>
<td>76</td>
</tr>
<tr>
<td>Nienhaus et al 40</td>
<td>2007</td>
<td>Germany</td>
<td>454</td>
<td></td>
<td>QFT-G-IT</td>
<td>42</td>
</tr>
<tr>
<td>Nienhaus et al 41</td>
<td>2007</td>
<td>Germany</td>
<td>161</td>
<td>2 TU</td>
<td>QFT-G-IT</td>
<td>36</td>
</tr>
<tr>
<td>Mirtskhulava et al 42</td>
<td>2008</td>
<td>Georgia</td>
<td>265</td>
<td>5 TU</td>
<td>QFT-G-IT</td>
<td>77.7</td>
</tr>
<tr>
<td>Hotta et al 43</td>
<td>2007</td>
<td>Japan</td>
<td>207</td>
<td>3 TU</td>
<td>QFT-TB-2G</td>
<td>92% (48% with &gt;1 BCG)</td>
</tr>
<tr>
<td>Nienhaus et al 44</td>
<td>2008</td>
<td>Germany</td>
<td>261</td>
<td>2 TU</td>
<td>QFT-G-IT</td>
<td>37.5</td>
</tr>
<tr>
<td>Ciacchetti et al 45</td>
<td>2007</td>
<td>Italy</td>
<td>590</td>
<td></td>
<td>QFT-G</td>
<td>56</td>
</tr>
<tr>
<td>Eum et al 46,37</td>
<td>2008</td>
<td>Republic of Korea</td>
<td>73</td>
<td></td>
<td>QFT-G-IT</td>
<td>100</td>
</tr>
<tr>
<td>Choi et al 47,48</td>
<td>2008</td>
<td>Republic of Korea</td>
<td>84</td>
<td>2 TU</td>
<td>QFT-G</td>
<td>100</td>
</tr>
<tr>
<td>Carvalho et al 48</td>
<td>2008</td>
<td>Italy</td>
<td>65</td>
<td>5 IU</td>
<td>QFT-G</td>
<td>85</td>
</tr>
<tr>
<td>Barsegian et al 49</td>
<td>2008</td>
<td>Germany</td>
<td>95</td>
<td></td>
<td>T-SPOT.TB</td>
<td>36</td>
</tr>
<tr>
<td>Stebler et al 50</td>
<td>2008</td>
<td>Switzerland</td>
<td>777</td>
<td></td>
<td>QFT-G-IT</td>
<td>87.4</td>
</tr>
<tr>
<td>Thijens et al 41</td>
<td>2008</td>
<td>The Netherlands</td>
<td>19</td>
<td></td>
<td>QFT-G-IT and T-SPOT.TB</td>
<td>16</td>
</tr>
<tr>
<td>Demkov et al 52</td>
<td>2008</td>
<td>Poland</td>
<td>155</td>
<td></td>
<td>QFT-G</td>
<td>100</td>
</tr>
<tr>
<td>Schablon et al 53</td>
<td>2009</td>
<td>Germany</td>
<td>270</td>
<td></td>
<td>QFT-G-IT</td>
<td>52.8</td>
</tr>
<tr>
<td>Dorman et al 54</td>
<td>2009</td>
<td>USA</td>
<td>1313</td>
<td></td>
<td>QFT-G-IT and T-SPOT.TB</td>
<td>—</td>
</tr>
<tr>
<td>Mehta et al 55</td>
<td>2009</td>
<td>USA</td>
<td>12†</td>
<td></td>
<td>QFT-G</td>
<td>—</td>
</tr>
<tr>
<td>Vinton et al 56</td>
<td>2009</td>
<td>Australia</td>
<td>481</td>
<td>10 IU</td>
<td>QFT-G-IT</td>
<td>78</td>
</tr>
<tr>
<td>Zinski Topic et al 57</td>
<td>2009</td>
<td>Croatia</td>
<td>54</td>
<td>2 TU</td>
<td>QFT-G-IT</td>
<td>100</td>
</tr>
<tr>
<td>Khanna et al 43</td>
<td>2009</td>
<td>UK</td>
<td>171</td>
<td>2 TU</td>
<td>QFT-G-IT</td>
<td>82.5</td>
</tr>
<tr>
<td>Alvarez-Leon et al 58</td>
<td>2009</td>
<td>Spain</td>
<td>134</td>
<td>2 TU</td>
<td>QFT-G-IT</td>
<td>35</td>
</tr>
<tr>
<td>Casas et al 59</td>
<td>2009</td>
<td>Spain</td>
<td>147</td>
<td>2 TU</td>
<td>T-SPOT.TB &amp; QFT-G-IT</td>
<td>16</td>
</tr>
<tr>
<td>Fox et al 61,62</td>
<td>2009</td>
<td>Israel</td>
<td>100</td>
<td>5 PPD</td>
<td>QFT-G-IT</td>
<td>37</td>
</tr>
<tr>
<td>Costa et al 53,53,63</td>
<td>2009</td>
<td>Portugal</td>
<td>1218</td>
<td>2 TU</td>
<td>QFT-G-IT</td>
<td>100</td>
</tr>
<tr>
<td>Zhao et al 64</td>
<td>2009</td>
<td>USA</td>
<td>40</td>
<td></td>
<td>QFT-G-IT</td>
<td>—</td>
</tr>
<tr>
<td>Girardi et al 65</td>
<td>2009</td>
<td>Italy</td>
<td>115</td>
<td>5 IU</td>
<td>T-SPOT.TB and QFT-G-IT</td>
<td>37.4</td>
</tr>
<tr>
<td>Cummings et al 66</td>
<td>2009</td>
<td>USA</td>
<td>182</td>
<td></td>
<td>QFT-G-IT</td>
<td>7</td>
</tr>
</tbody>
</table>

*Two studies based on same cohort, ERJ data displayed in table.

†All subjects were TST converters at recruitment.

BCG, Bacille Calmette-Guerin vaccine; HCW, healthcare worker; IGRA, interferon-gamma release assay; IU, international unit; PPD, purified protein derivative; QFT, QuantiFERON test; QFT-G, QFT Gold test; QFT-G-IT, QFT Gold In-Tube test; TB, tuberculosis; TST, tuberculin skin test; TU, tuberculin unit.

### Longitudinal serial testing IGRA studies and their results

IGRA conversion and reversion rates in HCW populations in high-incidence countries

We identified only two serial testing studies from high-incidence settings. Studies conducted repeat testing at 0, 6 and 12 months, and 0 and 18 months (table 2).15 The rates of IGRA conversions from these two studies ranged from 11.6% to 21%. The study by Pai et al was the only study to calculate the TST conversion rate and found a 4% rate after 18 months.15 Pai et al also found conversions rates varied for both the TST and the IGRA.

### Table 2  Characteristics of eight longitudinal and serial testing IGRA studies in HCWs

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Country</th>
<th>N</th>
<th>TST (PPD dose)</th>
<th>IGRA (QFT, TSPOT.TB or both)</th>
<th>Timing between repeat testing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High TB incidence countries</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pai et al 25,26,27</td>
<td>2006</td>
<td>India</td>
<td>216</td>
<td>1 TU</td>
<td>QFT-G-IT</td>
<td>18 months</td>
</tr>
<tr>
<td>Joshi et al 48,49</td>
<td>2009</td>
<td>India</td>
<td>79</td>
<td></td>
<td>QFT-G-IT</td>
<td>0, 6 and 12 months</td>
</tr>
<tr>
<td><strong>Intermediate and low TB incidence countries</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pollock et al 57</td>
<td>2009</td>
<td>USA</td>
<td>143</td>
<td>5 TU</td>
<td>QFT-G-IT and T-SPOT.TB</td>
<td>1—7 months</td>
</tr>
<tr>
<td>Zverling et al 60</td>
<td>2009</td>
<td>Canada</td>
<td>117</td>
<td>5 TU</td>
<td>QFT-G-IT</td>
<td>1 year</td>
</tr>
<tr>
<td>Yoshihaya et al 61</td>
<td>2009</td>
<td>Japan</td>
<td>311</td>
<td></td>
<td>QFT-G</td>
<td>2 and 4 years</td>
</tr>
<tr>
<td>Chee et al 62,63</td>
<td>2009</td>
<td>Singapore</td>
<td>207</td>
<td>2 TU</td>
<td>T-SPOT.TB</td>
<td>1 year</td>
</tr>
<tr>
<td>Lee et al, ICHE 64,65</td>
<td>2009</td>
<td>Republic of Korea</td>
<td>196</td>
<td>2 TU</td>
<td>QFT-G</td>
<td>1 year</td>
</tr>
<tr>
<td>Bellnap et al 66,67</td>
<td>2010</td>
<td>USA</td>
<td>1291</td>
<td>5 TU</td>
<td>QFT-G-IT and T-SPOT.TB</td>
<td>6 months</td>
</tr>
<tr>
<td>Costa et al 68,69</td>
<td>2010</td>
<td>Portugal</td>
<td>670</td>
<td>2 TU</td>
<td>QFT-G-IT</td>
<td>1—2.5 years</td>
</tr>
<tr>
<td>Ringhausen et al 70,71</td>
<td>2010</td>
<td>Germany</td>
<td>182</td>
<td>2 TU</td>
<td>QFT-G-IT</td>
<td>18 weeks</td>
</tr>
</tbody>
</table>

HCW, healthcare worker; IGRA, interferon-gamma release assay; IU, international unit; PPD, purified protein derivative; QFT, QuantiFERON test; QFT-G, QFT Gold test; QFT-G-IT, QFT Gold In-Tube test; TB, tuberculosis; TST, tuberculin skin test; TU, tuberculin unit.
IGRA when different cut-offs were used. Neither study reported data to suggest that IGRA conversions were better associated with TB exposure than TST conversions.

Reversion rates in the study by Joshi et al ranged from 27% in the first 6-month period to 40% in the second 6-month period.58 Pai et al reported 18-month IGRA reversion rates around 7% among baseline concordant positives, but up to 70% among those with discordant baseline results (ie, TST+/IGRA-).15

IGRA and TST conversion and reversion rates in HCW populations in low-incidence countries

Four studies have been recently published in this area, while two others were presented at conferences in 2009 and 2010 (table 2).59–64 As summarised in table 3, conversion rates ranged from 1.8% (5/277) in Japan60 (testing every 2 years) to 14.4% (21/146) in Korea62 (testing every year). A study by Lee et al62 was the only one to report a higher TST conversion rate than IGRA conversion rate (21% vs 14%). Yoshiyama et al in Japan60 and Pollock et al in the USA64 found IGRA conversions were associated with TB exposure; however, neither performed repeat TST. Bellknap et al found IGRA conversion rates were associated with older age and male gender but not occupational exposure to patients with active TB.65 In the only published study to examine the association of IGRA and TST conversions with exposure to TB,62 occupational TB exposure was not associated with TST or IGRA conversions.

Three studies from low- and moderate-incidence settings including Japan,60 Canada59 and the USA reported IGRA reversion rates of 40–52.9%.63-65 In the Japanese study, where participants were tested at baseline, at 2 years and at 4 years, all reversions had initial interferon-gamma values close to the cut-off.58 This study also showed that QFT conversion was associated with working in a TB ward. A study from Canada found half of the subjects with discordant baseline results (QFT+/TST−) reverted to negative QFT at 1 year. TST was not repeated if the participant was TST+.63 so these studies were not able to estimate TST reversions.

The two most recent serial testing publications in HCWs confirm these early findings. Ringshausen et al in Germany reported a large reversion rate (6/18, 33%) while only 3/162 (1.9%) reported IGRA conversions and demonstrated that, when continuous IGRA results were employed, higher baseline results were more stable than those closer to the cut-off.21 Costa et al found conversion rates of 3.6–11% and reversion rates of 5.2–22% depending on the cut-off used. Using simple negative to positive cut-offs whether for reversions or conversions always gave the largest estimates (11% and 22%, respectively).

Overall, serial testing data from low-incidence countries suggest that IGRA results vary greatly during serial testing, and rates of conversions and reversions vary depending on the test used and the cut-off definition used. When simple negative/positive changes are used as cut-offs, IGRA had higher rates of reversions and conversions which were frequently higher than the TST. Owing to the limited number of studies evaluating conversions and a relationship between exposure, there are no data to show that IGRA are better at identifying the incidence of new TB infection than the TST.

**Figure 3** Cross-sectional studies in countries with a high incidence of tuberculosis (N=2). QFT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test.
Information on secondary outcomes including cost-effectiveness, feasibility and implementation are available in the online supplement.

**DISCUSSION**

While the TST has been successfully used in TBIC programmes, the availability and growing use of IGRAs raises the issue of whether IGRAs could replace the TST for screening of HCWs. Given the repeated nature of routine screening, there are particular issues which may not be relevant in routine practice or contact investigations but become very important when contemplating serial screening. These include test reproducibility, performance of IGRA when repeated frequently, interpretation of discordant TST and IGRA results and the interferon-gamma thresholds (cut-off values) which most accurately distinguish new TB infection (ie, conversion) from random variation. Despite the paucity of data on the above critical issues, some countries such as the USA have recommended the use of IGRAs for HCW screening. In contrast, other guidelines (eg, Canada, Australia, UK) have been cautious. In June 2010 the US Centers for Disease Control (CDC) released an updated guideline on IGRAs. This guideline is more cautious about serial testing with IGRAs and emphasises that using a ‘lenient criterion to define IGRA conversion might produce more conversions than are observed with the more stringent criteria applied to TSTs. Furthermore, an association between an IGRA conversion and subsequent disease risk has
Table 3: Summary of rates of conversions and reversions in serial testing studies (N=8)

<table>
<thead>
<tr>
<th>Study</th>
<th>Duration between testing</th>
<th>TST converters, n/N (%)</th>
<th>IGRA converters, n/N (%)</th>
<th>IGRA reverters, n/N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High TB incidence countries</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pai, 2008</td>
<td>18 months</td>
<td>6/147 (4.1%)</td>
<td>17/147 (11.8%)</td>
<td>7/38 (18.4%)</td>
</tr>
<tr>
<td>Joshi, 2009</td>
<td>6 months</td>
<td>—</td>
<td>11/57 (19%)</td>
<td>6/22 (27%)</td>
</tr>
<tr>
<td></td>
<td>6 months (6–12 months)</td>
<td>—</td>
<td>11/52* (21%)</td>
<td>11/27† (40%)</td>
</tr>
<tr>
<td>Moderate and low TB incidence countries</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pollock, 2009</td>
<td>1–7 months</td>
<td>—</td>
<td>2/42‡ (4.6%)</td>
<td>—</td>
</tr>
<tr>
<td>Zwerling, 2009</td>
<td>1 year</td>
<td>0/57 (0%)</td>
<td>4/56 (7.14%)</td>
<td>4/5 (80%)</td>
</tr>
<tr>
<td>Yoshiyama, 2009</td>
<td>2 and 4 years</td>
<td>—</td>
<td>5/277 (1.8%)</td>
<td>13/32 (41%)</td>
</tr>
<tr>
<td>Chee, 2009</td>
<td>1 year</td>
<td>0/18‡</td>
<td>9/162 (4.9%)</td>
<td>—</td>
</tr>
<tr>
<td>Lee, 2009</td>
<td>1 year</td>
<td>16/75 (21.3%)</td>
<td>21/146 (14.4%)</td>
<td>—</td>
</tr>
<tr>
<td>Belknap, 2010</td>
<td>6 months</td>
<td>4/1202 (0.3%)</td>
<td>TSPOT 44/1117 (3.9%)</td>
<td>TSPOT 36/68 (52.9%)</td>
</tr>
<tr>
<td>Costa, 2010</td>
<td>1–2.5 years</td>
<td>98/199 (49.2%)</td>
<td>51/462 (11%)</td>
<td>46/208 (22.1%)</td>
</tr>
<tr>
<td>Ringshausen, 2010</td>
<td>18 weeks</td>
<td>(baseline only)</td>
<td>3/162 (1.9%)</td>
<td>6/18 (33.3%)</td>
</tr>
</tbody>
</table>

All conversions/reversions using simple negative/positive definition.
*Denominator includes only participants positive at 6 months.
†Denominator includes only participants positive at 6 months.
‡Denominator includes only baseline concordant negatives.
IGRA, interferon-gamma release assay; PPD, purified protein derivative; TB, tuberculosis; TST, tuberculin skin test.

not been demonstrated. The criteria for interpreting changes in an IGRA that identify new infections remain uncertain. Likewise, the most recent 2010 Canadian guidelines also called for caution in the use of IGRA s in serial testing. In December 2010, the WHO released a STAG report including recommendations which discourage the use of IGRA s, “for the detection of latent TB infection (LTBI) in adults, children, health-care workers, contacts and those involved in outbreak investigations in low-income and middle-income countries.” This move towards more cautious guidelines in the domain of serial testing is supported by findings in our review, and reinforces the need for an addendum to existing guidelines on IGRA s that specifically addresses issues related to interpretation of conversions and reversions.

Our systematic review provides several useful insights into the performance of IGRA s in HCWs. The observed prevalence of LTBI in HCWs depends on the test used and the particular TB incidence setting. In low-incidence countries IGRA s estimate a significantly lower prevalence of LTBI than the TST. Some attribute such discordance to the higher specificity of IGRA s compared with the TST and, indeed, agreement and $\kappa$ values are improved in non-BCG-vaccinated individuals compared with BCG-vaccinated, although there is not a strong trend (figure 4).

Studies have suggested that the lower prevalence of LTBI using IGRA s will result in fewer numbers of HCWs who require preventive therapy. However, the higher rate of subsequent conversions found by IGRA in these studies suggests that, while fewer individuals may be identified as LTBI at baseline, more individuals could be diagnosed with conversions by IGRA leading to more HCWs requiring preventive therapy upon repeated screening. This finding has major implications for TBIC policies and relevant cost-effectiveness analyses.

Along with high conversion rates, studies reported high rates of subsequent reversions. This poses concerns of both a scientific and clinical nature. What biological phenomenon is at work here? Are these individuals clearing the infection naturally? Is reinfection an issue in high TB incidence settings? Given a high expected reversion rate, should individuals with positive results be treated, or tested again at a later date? Treating individuals who might have reverted in the absence of treatment could create an environment where more individuals take potentially harmful preventive therapy unnecessarily. This has raised much interest in what is an appropriate definition for an IGRA conversion or reversion.

As summarised in a recent systematic review, within-subject reproducibility of IGRA s is moderate and a previous TST can potentially boost subsequent IGRA results. IGRA s are dynamic assays and interferon-gamma values tend to fluctuate around the cut-off and cause apparent conversions and reversions. The exact cause of the conversions and reversions remains unclear, and might indicate spontaneous clearance of TB infection, reinfection or dynamic changes within the spectrum of latent TB infection. Conversion rates are highest when a simple negative to positive change is used to define a conversion. This is also true for reversion rates where a simple positive to negative change is used as the definition. Our review suggests that this is true in both high- and low-incidence settings and has implications for deciding on criteria (cut-offs) for conversions and reversions. Alternatives to a simple negative to positive definition for conversion have been proposed by others, including definitions involving an absolute increase over baseline (similar to the TST), a proportionate increase over baseline or a proposed ‘grey zone’. These more stringent definitions may lead to smaller rates of conversions and reversions; however, it remains to be seen which conversion definition will be most strongly associated with TB exposure or subsequent disease development.

Studies found good correlation between occupational risk factors and positivity rates, but very few studies have looked at an association between IGRA test conversion and known occupational exposure or progression to disease. Without these, the interpretation and prognosis of conversions and reversions remains unclear.

Strengths and limitations of the review

Our systematic review had several strengths. We employed a comprehensive search strategy using multiple sources and databases to retrieve relevant studies, including unpublished studies and conference proceedings. Two review authors independently assessed eligible articles for inclusion. Owing to heterogeneity in study designs and outcomes assessed in each study, it was not appropriate to pool the data, and instead we analysed study results in subgroups by study design and by background TB incidence.
Despite the comprehensive search, we may have missed relevant studies and publication bias is always a concern. Furthermore, very few studies reported prevalence of HIV among their study populations. Lastly, there is lack of evidence at the highest level of the hierarchy of reference standards; a majority of the included studies were cross-sectional and predominantly from low TB incidence settings. Serial testing data, evidence on predictive value in HCWs and reproducibility data are still quite limited.

Research directions and implications

Until further evidence is available, TBIC programmes that include IGRA testing must use caution, as emphasised by recent programmes may observe higher conversion numbers with IGRA testing must use caution, as emphasised by recent guidelines and evidence available on the use of IGRAs, and health professionals should be cautious about using IGRA testing.]

Current guidelines and evidence available on the use of IGRAs do not adequately address questions raised by serial testing, nor do they provide the guidance or understanding needed to properly interpret IGRA results in serial testing. With rapidly accumulating evidence from serial testing studies, existing IGRA guidelines will need to be updated with specific recommendations on interpretation of serial testing results.

Acknowledgements

The authors thank WHO and EG members for their constructive feedback on the review.

Funding

This work was supported in part by USAID funding through TB CAP, the Canadian Institutes of Health Research (grant MOP-81362) and the Special Programme for Research and Training in Tropical Diseases (TDR). These agencies had no role in the design, execution or publication of this study. AZ is supported by a recipient of a CIHR New Investigator Award and DM is a recipient of a Fonds de la Recherche en santé du Québec (FRSQ) career award.

Competing interests

No financial conflicts. At the time this review was conducted MP served as an external consultant for the Foundation for Innovative New Diagnostics (FIND), Geneva, a non-profit agency that works with several industry partners including Cellceptis Ltd, Australia in developing and evaluating new diagnostic tools for neglected diseases.

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES

Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review

Alice Zwerling, Susan van den Hof, Jerod Scholten, Frank Cobelens, Dick Menzies and Madhukar Pai

Thorax 2012 67: 62-70 originally published online January 12, 2011
doi: 10.1136/thx.2010.143180

Updated information and services can be found at:
http://thorax.bmj.com/content/67/1/62

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2010/12/02/thx.2010.143180.DC1

References
This article cites 64 articles, 3 of which you can access for free at:
http://thorax.bmj.com/content/67/1/62#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Screening (epidemiology) (366)
- Screening (public health) (366)
- Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/